Inhibikase Therapeutics, Inc. Non Peo Neo Avg Comp Actually Paid Amt
Inhibikase Therapeutics, Inc. (IKT) reported Non Peo Neo Avg Comp Actually Paid Amt of $6.33 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-30.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-30
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $6.33M DEF 14A · filed 2026-04-30 |
| 2024-12-31 | $814.91K DEF 14A · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |